DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Anat Ashkenazi - 1 Eli Lilly Eli Lilly Alphabet's - 1 Ruth Porat - 1 Eli Lilly - 1 Ashkenazi - 1 it's - 1 Eli Lilly's - 1 David Ricks - 1
Top related locs:
U.S Indiana San Francisco Bay Davos Switzerland Israel biopharma North Carolina
Top related orgs:
San - 1 San Francisco Bay Area - 1 Google - 1 Economic - 1 Bloomberg - 1 Getty - 1 CNBC - 1 Tel Aviv University - 1

Search resuls for: "Eli Lilly's Covid"


3 mentions found


☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
  + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com   time to read: +10 min
Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.
Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey
☆ FDA pulls authorization for AstraZeneca’s Covid antibody drug Evusheld
  + stars: | 2023-01-27 | by ( ) www.nbcnews.com   time to read: +1 min
The Food and Drug Administration has withdrawn emergency use authorization for AstraZeneca’s Covid-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of omicron. Omicron subvariant XBB.1.5 has been spreading rapidly in the country since December and it made up nearly half of all U.S. Covid cases last week, according to government data. The drugmaker plans to continue to share relevant data with the FDA and other health authorities regarding Evusheld and SARS-CoV-2 variants. In November, the U.S. health regulator also pulled emergency use authorization for Eli Lilly's Covid drug bebtelovimab, citing similar concerns. Evusheld was first authorized in late 2021 by the FDA to prevent Covid infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
☆ FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
  + stars: | 2022-11-30 | by ( ) www.reuters.com   time to read: +1 min
Nov 30 (Reuters) - Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's (PFE.N) antiviral drug Paxlovid, Merck's (MRK.N) Lagevrio and Gilead Sciences' (GILD.O) Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people. The drug, which was discovered by Abcellera (ABCL.O) and commercialized by Eli Lilly, received an authorization from the FDA in February. BQ.1 and BQ.1.1 have become the dominant strains in the United States after a steady increase in prevalence over the last two months, surpassing Omicron's BA.5 sub-variant, which had driven cases earlier in the year.
0 next >>
Total: 3